BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30370255)

  • 1. PIM Kinase as an Executional Target in Cancer.
    Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
    J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.
    Wang Y; Xiu J; Ren C; Yu Z
    J Cancer; 2021; 12(9):2570-2581. PubMed ID: 33854618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM Kinases in Multiple Myeloma.
    Wu J; Chu E; Kang Y
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
    Atalay P; Ozpolat B
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
    Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
    Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
    ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
    Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
    Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 May; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Alsubaie M; Matou-Nasri S; Aljedai A; Alaskar A; Al-Eidi H; Albabtain SA; Aldilaijan KE; Alsayegh M; Alabdulkareem IB
    Oncol Lett; 2021 Aug; 22(2):622. PubMed ID: 34267815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
    Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.
    Aguirre E; Renner O; Narlik-Grassow M; Blanco-Aparicio C
    Front Oncol; 2014; 4():109. PubMed ID: 24860787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.
    Andina N; Didichenko S; Schmidt-Mende J; Dahinden CA; Simon HU
    J Allergy Clin Immunol; 2009 Mar; 123(3):603-11. PubMed ID: 19152965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PIM family of serine/threonine kinases in cancer.
    Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.